|
JP2007500508A
(ja)
*
|
2003-07-29 |
2007-01-18 |
モルフォテック、インク． |
抗体とエフェクター機能が増強された遺伝子組み換え抗体を作成する方法
|
|
AU2005214331B2
(en)
*
|
2004-02-12 |
2011-09-15 |
Eisai, Inc. |
Monoclonal antibodies that specifically bind to folate receptor alpha
|
|
AU2006223301B2
(en)
*
|
2005-03-10 |
2010-11-04 |
Eisai, Inc. |
Anti-mesothelin antibodies
|
|
EP2172487A1
(en)
|
2005-04-22 |
2010-04-07 |
Morphotek Inc. |
Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
|
|
KR100694508B1
(ko)
*
|
2005-05-24 |
2007-03-13 |
울산대학교 산학협력단 |
Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
|
|
US7943133B2
(en)
*
|
2006-02-02 |
2011-05-17 |
Boston Biocom Llc |
Mesothelin antibody protein fusions and methods of use
|
|
US7795411B2
(en)
|
2006-10-05 |
2010-09-14 |
Fred Hutchinson Cancer Research Center |
Vectors for expressing in vivo biotinylated recombinant proteins
|
|
MX2009004718A
(es)
*
|
2006-11-02 |
2009-06-19 |
Acceleron Pharma Inc |
Antagonistas de receptor de alk1 y ligando y sus usos.
|
|
AU2008308956B2
(en)
|
2007-10-01 |
2013-03-14 |
Bristol-Myers Squibb Company |
Human antibodies that bind mesothelin, and uses thereof
|
|
JP5608091B2
(ja)
*
|
2007-11-26 |
2014-10-15 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
抗メソセリン抗体およびその使用
|
|
WO2009120769A1
(en)
*
|
2008-03-27 |
2009-10-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Human anti-mesothelin monoclonal antibodies
|
|
JP2010014691A
(ja)
*
|
2008-06-20 |
2010-01-21 |
Igaku Seibutsugaku Kenkyusho:Kk |
腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置
|
|
US8460660B2
(en)
*
|
2009-03-24 |
2013-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-mesothelin antibodies
|
|
AR076284A1
(es)
*
|
2009-04-29 |
2011-06-01 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
PH12012501884B1
(en)
|
2010-03-30 |
2018-04-13 |
Janssen Biotech Inc |
Humanized il-25 antibodies
|
|
NZ610976A
(en)
|
2010-12-20 |
2015-07-31 |
Genentech Inc |
Anti-mesothelin antibodies and immunoconjugates
|
|
US10233240B1
(en)
*
|
2011-04-18 |
2019-03-19 |
The Regents Of The University Of California |
Methods for treating cholestatic liver fibrosis
|
|
PH12013502264A1
(en)
|
2011-05-06 |
2019-03-22 |
Us Gov Health & Human Services |
Recombinant immunotoxin targeting mesothelin
|
|
BR112014019861A2
(pt)
*
|
2012-02-17 |
2017-07-04 |
Seattle Genetics Inc |
anticorpo, ácido nucleico isolado, método de tratamento de um paciente com câncer, e, composição farmacêutica de um anticorpo
|
|
WO2013142300A2
(en)
*
|
2012-03-20 |
2013-09-26 |
Biogen Idec Ma Inc. |
Jcv neutralizing antibodies
|
|
HUE044838T2
(hu)
|
2012-03-20 |
2019-11-28 |
Biogen Ma Inc |
JCV neutralizáló antitestek
|
|
CA3116051C
(en)
|
2012-03-23 |
2023-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
EP3327037B1
(en)
*
|
2012-08-21 |
2019-10-09 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
RS60615B1
(sr)
|
2014-11-20 |
2020-08-31 |
Hoffmann La Roche |
Zajednički laki lanci i postupci upotrebe
|
|
SG11201702976TA
(en)
|
2014-11-20 |
2017-05-30 |
Hoffmann La Roche |
T cell activating bispecific antigen binding molecules agiant folr1 and cd3
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
EP3466967A1
(en)
|
2015-05-18 |
2019-04-10 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
NZ740855A
(en)
*
|
2015-08-21 |
2022-04-29 |
Crage Medical Co Ltd |
Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
|
|
KR101782487B1
(ko)
|
2015-09-24 |
2017-09-27 |
재단법인 목암생명과학연구소 |
신규 항-메소텔린 항체 및 이를 포함하는 조성물
|
|
AR106365A1
(es)
*
|
2015-10-02 |
2018-01-10 |
Hoffmann La Roche |
Moléculas biespecíficas de unión a antígeno activadoras de células t
|
|
EP3359168A4
(en)
|
2015-10-06 |
2019-08-07 |
Regents of the University of Minnesota |
THERAPEUTIC COMPOUNDS AND METHOD
|
|
SG11201805451TA
(en)
|
2015-12-30 |
2018-07-30 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
BR112018016281A2
(pt)
*
|
2016-03-22 |
2019-01-02 |
F. Hoffmann-La Roche Ag |
molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo
|
|
LT3433280T
(lt)
|
2016-03-22 |
2023-07-10 |
F. Hoffmann-La Roche Ag |
Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
IL262321B2
(en)
|
2016-04-15 |
2024-09-01 |
Novartis Ag |
Preparations and methods for selective protein expression
|
|
PT3448421T
(pt)
*
|
2016-04-29 |
2022-01-14 |
Univ Leland Stanford Junior |
Métodos e composições para a prevenção e tratamento de aderências cirúrgicas
|
|
CA3025345A1
(en)
|
2016-05-27 |
2017-11-30 |
Abbvie Biotherapeutics Inc. |
Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
MX2019001469A
(es)
|
2016-08-01 |
2019-10-02 |
Novartis Ag |
Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
|
|
AU2017306432A1
(en)
|
2016-08-02 |
2019-03-21 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
BR112019007100A2
(pt)
|
2016-10-07 |
2019-06-25 |
Tcr2 Therapeutics Inc |
composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
|
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
BR112019011186A2
(pt)
|
2016-12-01 |
2019-10-08 |
Regeneron Pharmaceuticals, Inc. |
conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
WO2018232020A1
(en)
|
2017-06-13 |
2018-12-20 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2019121906A1
(en)
|
2017-12-19 |
2019-06-27 |
F-Star Beta Limited |
Specific pd-l1 binding sequences inserted in a ch3 domain
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
US20210123075A1
(en)
|
2018-06-08 |
2021-04-29 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
KR20210022004A
(ko)
*
|
2018-06-18 |
2021-03-02 |
안위타 바이오사이언시스, 인코포레이티드 |
항-메소텔린 작제물 및 이의 용도
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
AU2019301204B2
(en)
|
2018-07-12 |
2025-10-23 |
Invox Pharma Limited |
Antibody molecules that bind PD-L1 and CD137
|
|
MX2021000399A
(es)
|
2018-07-12 |
2021-05-27 |
F Star Therapeutics Ltd |
Moleculas de anticuerpo que se unen a cd137 y ox40.
|
|
BR112021003416A2
(pt)
|
2018-08-30 |
2021-05-18 |
TCR2 Therapeutics Inc. |
composições e métodos para reprogramação de tcr usando proteínas de fusão
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN120535653A
(zh)
|
2018-10-19 |
2025-08-26 |
明尼苏达大学董事会 |
Nk接合子分子及其使用方法
|
|
WO2020092631A1
(en)
*
|
2018-10-31 |
2020-05-07 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for detecting and treating cancers characterized by expression of mesothelin
|
|
CN113271945A
(zh)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
|
|
CN112321714B
(zh)
*
|
2019-01-08 |
2022-06-28 |
上海霖科生物科技有限公司 |
与间皮素结合的单克隆抗体及其核酸分子
|
|
JP7483732B2
(ja)
|
2019-02-15 |
2024-05-15 |
ノバルティス アーゲー |
３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
MX2021015533A
(es)
*
|
2019-06-19 |
2022-02-10 |
Silverback Therapeutics Inc |
Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
|
|
AU2020397070A1
(en)
|
2019-12-05 |
2022-07-14 |
Seagen Inc. |
Anti-avb6 antibodies and antibody-drug conjugates
|
|
MX2022007688A
(es)
|
2019-12-20 |
2022-07-19 |
Amgen Inc |
Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
|
|
TW202135859A
(zh)
|
2019-12-20 |
2021-10-01 |
瑞士商諾華公司 |
組合療法
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
TW202321296A
(zh)
|
2021-10-06 |
2023-06-01 |
美商鏈接免疫療法公司 |
抗間皮素抗原結合分子及其用途
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
CN121038806A
(zh)
|
2023-04-25 |
2025-11-28 |
阿森纳生物科学公司 |
用于转录调控的新颖受体
|
|
CN120981456A
(zh)
|
2023-05-24 |
2025-11-18 |
金橘生物科技公司 |
杂环化合物及其用途
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|